Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
755 studies found for:    "Ovarian epithelial cancer"
Show Display Options
Rank Status Study
1 Completed
Has Results
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: tamoxifen citrate;   Drug: thalidomide;   Other: laboratory biomarker analysis
2 Completed
Has Results
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin;   Drug: alvocidib;   Drug: cisplatin/flavopiridol
3 Recruiting Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Conditions: Ovarian Neoplasms;   Ovarian Epithelial Cancer
Interventions: Biological: DCVAC/OvCa with Standard of Care;   Biological: DCVAC/OvCa sequentially chemotherapy;   Drug: Standard of Care
4 Terminated A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Condition: Epithelial Ovarian Cancer
Interventions: Drug: CAELYX;   Drug: Topotecan HCl
5 Completed EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Stage I Endometrial Carcinoma;   Stage I Ovarian Epithelial Cancer;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage II Endometrial Carcinoma;   Stage II Ovarian Epithelial Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Ovarian Epithelial Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Drug: EF5
6 Active, not recruiting OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Stage I Ovarian Epithelial Cancer;   Stage II Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: immunological adjuvant OPT-821;   Biological: polyvalent antigen-KLH conjugate vaccine;   Other: laboratory biomarker analysis
7 Recruiting Safety, Feasibility and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma
Condition: Ovarian Carcinoma
Interventions: Device: NovoTTF-100L(O);   Drug: Paclitaxel
8 Recruiting Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
Conditions: Ovarian Carcinoma;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Intervention: Procedure: HIPEC
9 Unknown  Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
Condition: Ovarian Carcinoma
Intervention: Other: timing of surgery
10 Completed A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
Conditions: Ovarian Carcinoma;   Relapse
Interventions: Drug: Oxaliplatin;   Drug: oxaliplatin
11 Completed Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
Conditions: Ovarian Carcinoma;   Recurrent Endometrial Carcinoma
Intervention: Drug: Tc 99m EC20
12 Withdrawn Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
Condition: Ovarian Carcinoma
Intervention: Drug: Fondaparinux
13 Completed Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Dietary Supplement: Early post-operative enteral feeding
14 Unknown  Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention:
15 Active, not recruiting Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor;   Recurrent Ovarian Epithelial Cancer;   Stage III Borderline Ovarian Surface Epithelial-stromal Tumor;   Stage III Ovarian Epithelial Cancer;   Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor;   Stage IV Ovarian Epithelial Cancer
Intervention: Drug: belinostat
16 Withdrawn Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity
Condition: Recurrent Ovarian Carcinoma
Interventions: Drug: Cisplatin;   Radiation: Whole Abdomen Radiotherapy
17 Withdrawn Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: oregovomab;   Drug: cyclophosphamide;   Procedure: laboratory biomarker analysis
18 Active, not recruiting Search for Predictors of Therapeutic Response in Ovarian Carcinoma
Conditions: Carcinoma of the Ovary;   Fallopian Tube Cancer;   Peritoneal Serous-type Advanced Stage
Intervention: Other: blood samples
19 Completed Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Biological: recombinant interleukin-12
20 Recruiting Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART) With Carboplatin and Docetaxel in Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Carcinoma;   Recurrent Ovarian Cancer;   Recurrent Ovarian Carcinoma
Interventions: Radiation: Low Dose Fractionated Whole Abdominal Radiation Therapy;   Drug: Carboplatin;   Drug: Docetaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years